PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles The Lancet Infectious Diseases Year : 2020

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Laura Richert
Arnaud Chêne
Odile Launay
Benoit Gamain

Abstract

PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant.
Bundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.
Fichier principal
Vignette du fichier
THELANCETID-HAL version.pdf (2.71 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03161802 , version 2 (02-12-2020)
hal-03161802 , version 1 (08-03-2021)

Identifiers

Cite

Sodiomon B Sirima, Laura Richert, Arnaud Chêne, Amadou T Konate, Cécilia Campion, et al.. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. The Lancet Infectious Diseases, 2020, 20 (5), pp.585-597. ⟨10.1016/S1473-3099(19)30739-X⟩. ⟨hal-03161802v2⟩
473 View
654 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More